
MSD’s Deepak Khanna to chair American Pharmaceutical Group
pharmafile | March 17, 2011 | Appointment | Research and Development, Sales and Marketing | American Pharmaceutical Group, Deepak Khanna, MSD, merck sharp and dohme
Merck Sharp and Dohme’s UK managing director Deepak Khanna has been appointed chairman of the American Pharmaceutical Group.
The APG is a trade association for the seven largest US research-based biopharmaceutical companies operating in the UK – Abbott, Amgen, BMS, Janssen, Lilly, MSD and Pfizer.
Deepak said: “We are going through a period of almost unprecedented policy change in the UK, including major NHS structural reform, a new medicines’ pricing system and the Cancer Drugs Fund.
“Throughout this time, the APG has an important role. We must work closely with the ABPI and others in industry and the government to ensure the result is the right operating environment in the UK. Only this will lead to the best possible health outcomes for patients and associated benefits to the UK’s economy. I look forward to working towards this goal.”
Deepak was appointed UK managing director of MSD in 2009, having previously served as general manager of Merck/Schering-Plough Pharmaceuticals in the US.
Related Content

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

Merck shares data from phase 3 trial of Keytruda for gastric cancers
Merck, known as MSD outside of the US and Canada, has announced data from the …

Merck to acquire Harpoon Therapeutics for approximately $680m
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced …






